Literature DB >> 16554534

Failure of ACAT inhibition to retard atherosclerosis.

Sergio Fazio, MacRae Linton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16554534     DOI： 10.1056/NEJMe068012

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Synthesis and Evaluation of 11C- and 18F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents.

Authors:  James R Hill; Xia Shao; Jay S Wright; Jenelle Stauff; Phillip S Sherman; Janna Arteaga; Ka Kit Wong; Benjamin L Viglianti; Peter J H Scott; Allen F Brooks
Journal:  ACS Med Chem Lett       Date:  2020-04-30       Impact factor: 4.345

2.  Identification of potential ACAT-2 selective inhibitors using pharmacophore, SVM and SVR from Chinese herbs.

Authors:  Lian-Sheng Qiao; Xian-Bao Zhang; Lu-di Jiang; Yan-Ling Zhang; Gong-Yu Li
Journal:  Mol Divers       Date:  2016-06-21       Impact factor: 2.943

3.  Novel lipid droplet-associated serine hydrolase regulates macrophage cholesterol mobilization.

Authors:  Young-Hwa Goo; Se-Hee Son; Paul B Kreienberg; Antoni Paul
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-12-19       Impact factor: 8.311

4.  Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Authors:  Yong Yang; Yan-Fu Wang; Xiao-Fang Yang; Zhao-Hui Wang; Yi-Tian Lian; Ying Yang; Xiao-Wei Li; Xiang Gao; Jian Chen; Yan-Wen Shu; Long-Xian Cheng; Yu-Hua Liao; Kun Liu
Journal:  J Lipid Res       Date:  2012-10-24       Impact factor: 5.922

5.  New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models.

Authors:  Taichi Ohshiro; Masaki Ohtawa; Tohru Nagamitsu; Daisuke Matsuda; Hiroaki Yagyu; Matthew A Davis; Lawrence L Rudel; Shun Ishibashi; Hiroshi Tomoda
Journal:  J Pharmacol Exp Ther       Date:  2015-09-03       Impact factor: 4.030

6.  Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content.

Authors:  Chetan P Hans; Mourad Zerfaoui; Amarjit S Naura; Dana Troxclair; Jack P Strong; Khalid Matrougui; A Hamid Boulares
Journal:  J Pharmacol Exp Ther       Date:  2009-01-05       Impact factor: 4.030

7.  ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity.

Authors:  James X Rong; Courtney Blachford; Jonathan E Feig; Ilda Bander; Jeffrey Mayne; Jun Kusunoki; Christine Miller; Matthew Davis; Martha Wilson; Shirley Dehn; Edward Thorp; Ira Tabas; Mark B Taubman; Lawrence L Rudel; Edward A Fisher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-08       Impact factor: 8.311

8.  Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet?

Authors:  Stephanie Seneff; Glyn Wainwright; Luca Mascitelli
Journal:  Arch Med Sci       Date:  2011-03-08       Impact factor: 3.318

9.  Short-Term Acyl-CoA:Cholesterol Acyltransferase Inhibition, Combined with Apoprotein A1 Overexpression, Promotes Atherosclerosis Inflammation Resolution in Mice.

Authors:  Jaume Amengual; Yoscar Ogando; Cyrus Nikain; Alexandra Quezada; Kun Qian; Tomas Vaisar; Edward A Fisher
Journal:  Mol Pharmacol       Date:  2020-12-31       Impact factor: 4.436

10.  Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice.

Authors:  Matteo Pedrelli; Padideh Davoodpour; Chiara Degirolamo; Monica Gomaraschi; Mark Graham; Alice Ossoli; Lilian Larsson; Laura Calabresi; Jan-Åke Gustafsson; Knut R Steffensen; Mats Eriksson; Paolo Parini
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.